BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene. 2013;32:3915-3921. [PMID: 22986530 DOI: 10.1038/onc.2012.403] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Barrett C, Budhiraja A, Parashar V, Batish M. The Landscape of Regulatory Noncoding RNAs in Ewing's Sarcoma. Biomedicines 2021;9:933. [PMID: 34440137 DOI: 10.3390/biomedicines9080933] [Reference Citation Analysis]
2 Owens C, Abbott LS, Gupta AA. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr Drugs 2013;15:473-92. [PMID: 23760780 DOI: 10.1007/s40272-013-0037-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Feng K, Liu Y, Xu LJ, Zhao LF, Jia CW, Xu MY. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor. Biomed Pharmacother 2018;104:686-98. [PMID: 29803929 DOI: 10.1016/j.biopha.2018.05.078] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
4 Li Q, Song S, Ni G, Li Y, Wang X. Serum miR-542-3p as a prognostic biomarker in osteosarcoma. Cancer Biomark 2018;21:521-6. [PMID: 29103020 DOI: 10.3233/CBM-170255] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
5 Roberto GM, Vieira GM, Delsin LEA, Silva MDO, Hakime RG, Engel EE, Scrideli CA, Tone LG, Brassesco MS. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor. Cancer Genetics 2019;230:21-7. [DOI: 10.1016/j.cancergen.2018.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Dai X, Theobard R, Cheng H, Xing M, Zhang J. Fusion genes: A promising tool combating against cancer. Biochim Biophys Acta Rev Cancer 2018;1869:149-60. [PMID: 29357299 DOI: 10.1016/j.bbcan.2017.12.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
7 Zhang R, Yan S, Wang J, Deng F, Guo Y, Li Y, Fan M, Song Q, Liu H, Weng Y, Shi Q. MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2. Tumour Biol 2016;37:3479-88. [PMID: 26449831 DOI: 10.1007/s13277-015-4086-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
8 Huijbers EJM, van der Werf IM, Faber LD, Sialino LD, van der Laan P, Holland HA, Cimpean AM, Thijssen VLJL, van Beijnum JR, Griffioen AW. Targeting Tumor Vascular CD99 Inhibits Tumor Growth. Front Immunol 2019;10:651. [PMID: 31001265 DOI: 10.3389/fimmu.2019.00651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
9 Sevim H, Çelik H, Düşünceli L, Ceyhan CS, Molotkova A, Nakazawa K, Graham GT, Petro JR, Toretsky JA, Üren A. Clofarabine induces ERK/MSK/CREB activation through inhibiting CD99 on Ewing sarcoma cells. PLoS One 2021;16:e0253170. [PMID: 34133426 DOI: 10.1371/journal.pone.0253170] [Reference Citation Analysis]
10 Rao DD, Jay C, Wang Z, Luo X, Kumar P, Eysenbach H, Ghisoli M, Senzer N, Nemunaitis J. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Mol Ther 2016;24:1412-22. [PMID: 27166877 DOI: 10.1038/mt.2016.93] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
11 Chen Z, Zhang J, Zhang Z, Feng Z, Wei J, Lu J, Fang Y, Liang Y, Cen J, Pan Y, Huang Y, Zhou F, Chen W, Luo J. The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell Death Dis 2017;8:e2859. [PMID: 28569782 DOI: 10.1038/cddis.2017.252] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
12 Pasello M, Manara MC, Scotlandi K. CD99 at the crossroads of physiology and pathology. J Cell Commun Signal 2018;12:55-68. [PMID: 29305692 DOI: 10.1007/s12079-017-0445-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
13 Manara MC, Pasello M, Scotlandi K. CD99: A Cell Surface Protein with an Oncojanus Role in Tumors. Genes (Basel) 2018;9:E159. [PMID: 29534016 DOI: 10.3390/genes9030159] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
14 Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing's sarcoma. Cell Prolif 2015;48:1-6. [PMID: 25530497 DOI: 10.1111/cpr.12160] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
15 Dylla L, Jedlicka P. Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma. PLoS One 2013;8:e63032. [PMID: 23638178 DOI: 10.1371/journal.pone.0063032] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
16 Kim SK, Park YK. Ewing sarcoma: a chronicle of molecular pathogenesis. Hum Pathol. 2016;55:91-100. [PMID: 27246176 DOI: 10.1016/j.humpath.2016.05.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
17 Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, Dirksen U, Bouvier C, de Pinieux G, Snaar-Jagalska E, Chavrier P, Delattre O. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene 2017;36:3505-14. [PMID: 28135250 DOI: 10.1038/onc.2016.498] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 16.4] [Reference Citation Analysis]
18 Yang X, Zhong X, Tanyi JL, Shen J, Xu C, Gao P, Zheng TM, DeMichele A, Zhang L. mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells. Biochem Biophys Res Commun. 2013;431:617-622. [PMID: 23274497 DOI: 10.1016/j.bbrc.2012.12.083] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 6.9] [Reference Citation Analysis]
19 Parrish JK, Sechler M, Winn RA, Jedlicka P. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene 2015;34:257-62. [PMID: 24362521 DOI: 10.1038/onc.2013.541] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
20 Zhou F, Elzi DJ, Jayabal P, Ma X, Chiu YC, Chen Y, Blackman B, Weintraub ST, Houghton PJ, Shiio Y. GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth. Cell Rep 2020;33:108332. [PMID: 33147457 DOI: 10.1016/j.celrep.2020.108332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif 2014;47:152-60. [PMID: 24517182 DOI: 10.1111/cpr.12093] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 8.8] [Reference Citation Analysis]
22 Dylla L, Moore C, Jedlicka P. MicroRNAs in Ewing Sarcoma. Front Oncol 2013;3:65. [PMID: 23543617 DOI: 10.3389/fonc.2013.00065] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
23 Tao J, Cong H, Wang H, Zhang D, Liu C, Chu H, Qing Q, Wang K. MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1. Biochem Biophys Res Commun 2018;503:1092-7. [PMID: 29936179 DOI: 10.1016/j.bbrc.2018.06.121] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
24 Lawlor ER, Sorensen PH. Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward? Crit Rev Oncog 2015;20:155-71. [PMID: 26349414 DOI: 10.1615/critrevoncog.2015013553] [Cited by in Crossref: 66] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
25 Che M, Gong W, Zhao Y, Liu M. Long noncoding RNA HCG18 inhibits the differentiation of human bone marrow-derived mesenchymal stem cells in osteoporosis by targeting miR-30a-5p/NOTCH1 axis. Mol Med 2020;26:106. [PMID: 33176682 DOI: 10.1186/s10020-020-00219-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kelly LC, Lázaro A, O'Sullivan MJ. What Do We Know about the Role of miRNAs in Pediatric Sarcoma? Int J Mol Sci 2015;16:16593-621. [PMID: 26204834 DOI: 10.3390/ijms160716593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, Yu H. Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer. Oncotarget. 2015;6:8579-8592. [PMID: 25865225 DOI: 10.18632/oncotarget.3287] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
28 Huang Q, Jiang Z, Meng T, Yin H, Wang J, Wan W, Cheng M, Yan W, Liu T, Song D, Chen H, Wu Z, Xu W, Li Z, Zhou W, Xiao J. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone. Biochemical and Biophysical Research Communications 2014;453:160-5. [DOI: 10.1016/j.bbrc.2014.09.076] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
29 Lim HJ, Yang J. Regulatory roles and therapeutic potential of microRNA in sarcoma. Critical Reviews in Oncology/Hematology 2016;97:118-30. [DOI: 10.1016/j.critrevonc.2015.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
30 Mariño-enríquez A, Fletcher CD. Round cell sarcomas – Biologically important refinements in subclassification. The International Journal of Biochemistry & Cell Biology 2014;53:493-504. [DOI: 10.1016/j.biocel.2014.04.022] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
31 Nugent M. MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag Res 2014;6:15-25. [PMID: 24426787 DOI: 10.2147/CMAR.S53928] [Cited by in Crossref: 54] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
32 Jiang LH, Zhang HD, Tang JH. MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer. J Oncol 2018;2018:5167829. [PMID: 30158978 DOI: 10.1155/2018/5167829] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
33 Yuan Y, Zheng S, Li Q, Xiang X, Gao T, Ran P, Sun L, Huang Q, Xie F, Du J, Xiao C. Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2. Acta Biochim Biophys Sin (Shanghai) 2016;48:220-8. [PMID: 26837415 DOI: 10.1093/abbs/gmv139] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
34 Yang XJ, Si RH, Liang YH, Ma BQ, Jiang ZB, Wang B, Gao P. Mir-30d increases intracellular survival of Helicobacter pylori through inhibition of autophagy pathway. World J Gastroenterol 2016; 22(15): 3978-3991 [PMID: 27099441 DOI: 10.3748/wjg.v22.i15.3978] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
35 Zhong J, Chen N, Chen X, Gong J, Nie L, Xu M, Zhou Q. Peripheral primitive neuroectodermal tumor of the kidney in a 51-year-old female following breast cancer: A case report and review of the literature. Oncol Lett. 2015;9:108-112. [PMID: 25435942 DOI: 10.3892/ol.2014.2695] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
36 Nugent M. microRNA and Bone Cancer. Adv Exp Med Biol 2015;889:201-30. [PMID: 26659003 DOI: 10.1007/978-3-319-23730-5_11] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
37 Al-Hussaini M, Dissi N, Souki C, Amayiri N. Atypical teratoid/ rhabdoid tumor, an immunohistochemical study of potential diagnostic and prognostic markers. Neuropathology 2016;36:17-26. [PMID: 26207291 DOI: 10.1111/neup.12231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
38 Iaquinta MR, Lanzillotti C, Mazziotta C, Bononi I, Frontini F, Mazzoni E, Oton-Gonzalez L, Rotondo JC, Torreggiani E, Tognon M, Martini F. The role of microRNAs in the osteogenic and chondrogenic differentiation of mesenchymal stem cells and bone pathologies. Theranostics 2021;11:6573-91. [PMID: 33995677 DOI: 10.7150/thno.55664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Montoya C, Rey L, Rodríguez J, Fernández MJ, Troncoso D, Cañas A, Moreno O, Henríquez B, Rojas A. Epigenetic control of the EWS‑FLI1 promoter in Ewing's sarcoma. Oncol Rep 2020;43:1199-207. [PMID: 32323788 DOI: 10.3892/or.2020.7489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Martinelli M, Parra A, Scapoli L, De Sanctis P, Chiadini V, Hattinger C, Picci P, Zucchini C, Scotlandi K. CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression. Oncotarget 2016;7:77958-67. [PMID: 27792997 DOI: 10.18632/oncotarget.12862] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kosela-Paterczyk H, Paziewska A, Kulecka M, Balabas A, Kluska A, Dabrowska M, Piatkowska M, Zeber-Lubecka N, Ambrozkiewicz F, Karczmarski J, Mikula M, Rutkowski P, Ostrowski J. Signatures of circulating microRNA in four sarcoma subtypes. J Cancer. 2020;11:874-882. [PMID: 31949491 DOI: 10.7150/jca.34723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
42 Çelik H, Sciandra M, Flashner B, Gelmez E, Kayraklıoğlu N, Allegakoen DV, Petro JR, Conn EJ, Hour S, Han J, Oktay L, Tiwari PB, Hayran M, Harris BT, Manara MC, Toretsky JA, Scotlandi K, Üren A. Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene 2018;37:2181-96. [PMID: 29382926 DOI: 10.1038/s41388-017-0080-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
43 Ventura S, Aryee DN, Felicetti F, De Feo A, Mancarella C, Manara MC, Picci P, Colombo MP, Kovar H, Carè A, Scotlandi K. CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling. Oncogene 2016;35:3944-54. [PMID: 26616853 DOI: 10.1038/onc.2015.463] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
44 Li DF, Yuan Y, Tu MJ, Hu X, Li YZ, Yi WR, Li PC, Zhao Y, Cheng Z, Yu AM, Jian C, Yu AX. The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug. Front Oncol 2020;10:222. [PMID: 32161722 DOI: 10.3389/fonc.2020.00222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Smith CM, Catchpoole D, Hutvagner G. Non-Coding RNAs in Pediatric Solid Tumors. Front Genet. 2019;10:798. [PMID: 31616462 DOI: 10.3389/fgene.2019.00798] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
46 Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res 2013;41:8853-71. [PMID: 23935076 DOI: 10.1093/nar/gkt678] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
47 Satterfield L, Shuck R, Kurenbekova L, Allen-Rhoades W, Edwards D, Huang S, Rajapakshe K, Coarfa C, Donehower LA, Yustein JT. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma. Int J Cancer 2017;141:2062-75. [PMID: 28748534 DOI: 10.1002/ijc.30909] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
48 Schwentner R, Herrero-Martin D, Kauer MO, Mutz CN, Katschnig AM, Sienski G, Alonso J, Aryee DN, Kovar H. The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma. Oncotarget 2017;8:10980-93. [PMID: 28030800 DOI: 10.18632/oncotarget.14091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
49 Viera GM, Salomao KB, de Sousa GR, Baroni M, Delsin LEA, Pezuk JA, Brassesco MS. miRNA signatures in childhood sarcomas and their clinical implications. Clin Transl Oncol 2019;21:1583-623. [PMID: 30949930 DOI: 10.1007/s12094-019-02104-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]